



1200 Liberty Ridge Drive
Suite 120
Wayne, PA 19087
888-290-0081
Xylocor.com

24Jun22

Clinical Study Protocol

Sponsor code XC001-1001

EudraCT number 2021-002803-37

A Phase 1/2 Trial of Direct Administration of AdVEGF-AII6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor, to the Ischemic Myocardium of Subjects with Angina Pectoris Secondary to Coronary Artery Disease that is Refractory to Drug Therapy and Unsuitable for Revascularization

This study was submitted to authorities; however, this study was not initiated in Poland. This study is being conducted in the United States and is currently ongoing. There are no results to report at this time.

Elizabeth Tarka, MD
Chief Medical Officer
XyloCor Therapeutics